Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5596739 | 0.90 | TDP1 (0.31) | TDP1 | |
| SCHEMBL5596714 | 0.86 | TDP1 (0.31) | TDP1 | |
| SCHEMBL17613644 | 0.81 | TDP1 (0.33) | TDP1ALDH1A1 | |
| SCHEMBL17599662 | 0.79 | TDP1 (0.32) | TDP1ALDH1A1 | |
| SCHEMBL12023038 | 0.79 | TSHR (0.46) | TDP1ALDH1A1 | |
| SCHEMBL10044377 | 0.79 | ALDH1A1 (0.43) | TDP1ALDH1A1 | |
| SCHEMBL5596429 | 0.78 | — | — | |
| SCHEMBL17613680 | 0.78 | TDP1 (0.31) | TDP1 | |
| SCHEMBL13639135 | 0.78 | ALDH1A1 (0.35) | TDP1ALDH1A1 | |
| SCHEMBL5597111 | 0.76 | TDP1 (0.30) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | TDP1 1733/4885ALDH1A1 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.